Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Carvedilol controlled-release - Chong Kun Dang

Next Previous
X
Search
Drug Profile

Carvedilol controlled-release - Chong Kun Dang

Alternative Names: Carvedilol sustained-release - Chong Kun Dang; CKD-825; Dilatrend SR

Latest Information Update: 01 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Chong Kun Dang
  • Class Antihypertensives; Carbazoles; Ethanolamines; Heart failure therapies; Ischaemic heart disorder therapies; Phenyl ethers; Propanolamines; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Alpha beta adrenergic receptor antagonists; Beta adrenergic receptor antagonists; Calcium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Angina pectoris; Essential hypertension; Heart failure
  • No development reported Atrial fibrillation

Most Recent Events

  • 30 Nov 2022 No development reported - Phase-III for Atrial fibrillation in South Korea (PO) (Chong Kun Dang Pharmaceutical pipeline, November 2022)
  • 23 Apr 2019 Phase III clinical trials in Atrial Fibrillation in South Korea (PO) (NCT03950843)
  • 30 Sep 2013 Chong Kun Dang completes a phase III trial in Essential hypertension in South Korea (NCT01756430)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top